These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 36433886)

  • 1. Dynamics of humoral and cellular immunity elicited by the BNT162b2 mRNA vaccine in psoriatic patients under targeted immunosuppression: A longitudinal cohort study.
    Zelini P; Isoletta E; Volontè M; Lilleri D; Cassaniti I; Musella V; Klersy C; Baldanti F; Brazzelli V
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e294-e296. PubMed ID: 36433886
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
    Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
    Front Immunol; 2022; 13():892277. PubMed ID: 35669765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of humoral and cellular immunity in vaccinated with mRNA-1273.
    Gutiérrez-Bautista JF; López-Nevot MÁ; Gómez-Vicente E; Quesada T; Marín EM; Rodríguez A; Rodríguez AI; Rodríguez-Granger J; Cobo F; Sampedro A
    APMIS; 2022 May; 130(5):261-269. PubMed ID: 35196403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2.
    Thieme CJ; Blazquez-Navarro A; Safi L; Kaliszczyk S; Paniskaki K; Neumann IE; Schmidt K; Stockhausen M; Hörstrup J; Cinkilic O; Flitsch-Kiefner L; Meister TL; Marheinecke C; Pfaender S; Steinmann E; Seibert FS; Stervbo U; Westhoff TH; Roch T; Babel N
    J Am Soc Nephrol; 2021 Nov; 32(11):2725-2727. PubMed ID: 34716240
    [No Abstract]   [Full Text] [Related]  

  • 5. Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study.
    Sugihara K; Wakiya R; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Ushio Y; Mizusaki M; Mino R; Chujo K; Nomura Y; Inoo M; Kadowaki N; Dobashi H
    Medicine (Baltimore); 2022 Oct; 101(42):e31288. PubMed ID: 36281134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.
    Miyakawa K; Kato H; Ohtake N; Jeremiah SS; Ryo A
    J Infect Dis; 2023 Jan; 227(2):221-225. PubMed ID: 35978486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
    Marking U; Bladh O; Aguilera K; Yang Y; Greilert Norin N; Blom K; Hober S; Klingström J; Havervall S; Åberg M; Sheward DJ; Thålin C
    Lancet Infect Dis; 2024 Feb; 24(2):e80-e81. PubMed ID: 38190833
    [No Abstract]   [Full Text] [Related]  

  • 9. Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis.
    Speer C; Töllner M; Benning L; Klein K; Bartenschlager M; Nusshag C; Kälble F; Reichel P; Schnitzler P; Zeier M; Morath C; Schmitt WH; Bergner R; Bartenschlager R; Schaier M
    Ann Rheum Dis; 2022 Apr; 81(4):593-595. PubMed ID: 35012926
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.
    Herzberg J; Fischer B; Lindenkamp C; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():839922. PubMed ID: 35309303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
    Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
    J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
    Stankov MV; Hoffmann M; Gutierrez Jauregui R; Cossmann A; Morillas Ramos G; Graalmann T; Winter EJ; Friedrichsen M; Ravens I; Ilievska T; Ristenpart J; Schimrock A; Willenzon S; Ahrenstorf G; Witte T; Förster R; Kempf A; Pöhlmann S; Hammerschmidt SI; Dopfer-Jablonka A; Behrens GMN
    Lancet Infect Dis; 2024 Jan; 24(1):e1-e3. PubMed ID: 37995739
    [No Abstract]   [Full Text] [Related]  

  • 13. Decline of immune humoral response after BNT162b2 vaccine.
    Ferri S; Polidoro A; Ciacciarelli M; Ceratti U; Congedo V; Mele M; Coluzzi G; Spagnoli A; Iuliano L
    J Infect; 2022 Apr; 84(4):e34-e35. PubMed ID: 35183610
    [No Abstract]   [Full Text] [Related]  

  • 14. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
    Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
    Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
    Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
    Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
    Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
    Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine.
    Uwamino Y; Kurafuji T; Takato K; Sakai A; Tanabe A; Noguchi M; Yatabe Y; Arai T; Ohno A; Tomita Y; Shibata A; Yokota H; Yamasawa W; Namkoong H; Sato Y; Hasegawa N; Wakui M; Murata M;
    Vaccine; 2022 Jul; 40(32):4538-4543. PubMed ID: 35718591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
    Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
    EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.